Pharma Rule 89(5) Inverted-Duty Refund Calculator

Rule 89(5) of the Central Goods and Services Tax Rules 2017 operationalises Section 54(3) of the CGST Act 2017, which grants a registered person a claim to refund of unutilised input tax credit (ITC) where the output tax rate on the outward supply is lower than the input tax rate on the inputs used to make that supply. This is the Inverted Duty Structure (IDS) refund. The formula, as amended by CBIC Notification 14/2022-CT dated 05-July-2022 and applicable to all refund applications on or after that date, is Maximum Refund Amount = {(Turnover of inverted-rated supply of goods) × Net ITC ÷ Adjusted Total Turnover} minus Tax payable on such inverted-rated supply. For an Indian pharma manufacturer, Rule 89(5) is the single most material working-capital instrument post the 56th GST Council decision of 03-September-2025 (effective 22-September-2025) which moved all drugs to a flat 5 percent output GST and all HSN 9018-9022 medical devices from 18 percent to 5 percent, while the input GST on formulation inputs, packaging (HSN Ch 39 plastic laminate and Ch 48 paperboard), excipients (mixed HSN Ch 12-35) and virtually all input services remains at 12-18 percent. GST Council FAQ Q10, Q25 and Q51 of the 56th Council explicitly acknowledged that the rate rationalisation deepens the inversion and pledged an expedited Section 54(3) refund cycle to manage the working-capital hit. Every formulation plant of every organised Indian pharma manufacturer — Sun Pharmaceutical Industries, Dr Reddy's Laboratories, Cipla, Aurobindo Pharma, Lupin, Zydus Lifesciences, Torrent Pharmaceuticals, Alkem Laboratories, Glenmark Pharmaceuticals, Cadila Pharmaceuticals — now runs a monthly RFD-01 filing cycle to convert the trapped Net ITC into a bank credit, and the reconciliation surface behind that filing is the difference between a healthy operating-cash profile and a stressed one.

CBIC Notification 14/2022-CT dated 05-July-2022 amended the definition of Net ITC in Rule 89(5) prospectively — refund applications filed on or after 05-July-2022 must use the amended formula; applications filed before that date use the pre-amendment definition. The amendment carved out two large ITC pools from Net ITC. First, the ITC availed on input services is excluded from Net ITC for Rule 89(5) purposes. Second, the ITC availed on capital goods is excluded from Net ITC for Rule 89(5) purposes. Only the ITC availed on inputs — goods — flows into the Net ITC numerator of the refund formula. This mirrors the constitutional position reasoned by the Supreme Court in Union of India v. VKC Footsteps India Pvt Ltd (2021) 10 SCC 674, which upheld the exclusion of input services from Rule 89(5) refund. For a pharma manufacturer, the cash impact is material. A large formulation plant may book ITC of Rs 40-60 crore per month on input services (contract research, technology-transfer consulting, USFDA remediation, CGMP audit fees, quality-assurance consulting, regulatory-affairs retainers, distribution logistics, warehouse rental, professional fees under Section 194J code 1005) and Rs 15-25 crore per month on capital goods (formulation equipment, packaging lines, quality-control instrumentation, ETP upgrades). Under the amended formula, none of that ITC is refundable under Rule 89(5) even though it is validly availed and reduces the plant's output-tax liability on non-inverted supplies. The refund is available only on the goods ITC (API, formulation drug inputs, packaging, excipients — HSN chapters 29, 30, 39, 48, 12-35 minus the Ch 27 solvent block, discussed separately below). This tool applies the amended formula strictly — input services ITC and capital goods ITC are captured for the audit trail but are subtracted out of the refund-eligible Net ITC.

CBIC Notification 09/2022-CT (Rate) dated 13-July-2022, effective 18-July-2022, invoked clause (ii) of the first proviso to Section 54(3) of the CGST Act 2017 to notify a list of goods where NO refund of unutilised ITC on account of inverted duty structure shall be allowed. Two chapter blocks were notified. First, HSN Chapter 15 — vegetable and animal fats and oils (the edible-oil sub-vertical). Second, HSN Chapter 27 — mineral fuels, mineral oils and products of their distillation. HSN Chapter 27 sweeps in the entire family of solvents used at scale in Active Pharmaceutical Ingredient (API) manufacture — n-hexane, isopropyl alcohol (IPA), methanol, ethanol (industrial), toluene, methyl ethyl ketone (MEK), acetone, dichloromethane. These are Chapter 27 goods carrying an input GST of 18 percent, purchased in bulk by every API manufacturer for extraction, crystallisation, chromatographic separation and formulation-transfer operations. Post 18-July-2022, the ITC availed on these Chapter 27 solvents remains legitimate and can be used to offset output tax on non-inverted supplies (it is not blocked ITC under Section 17), but it is BLOCKED from the Section 54(3) inverted-duty refund. For a large API manufacturer — Divi's Laboratories at Bollaram, Aurobindo Pharma's API divisions, Laurus Labs at Vishakhapatnam, Neuland Laboratories, Granules India, Suven Pharmaceuticals — the Chapter 27 solvent ITC can be Rs 10-30 crore per month per plant and would otherwise have been a very large chunk of the refund quantum. The block is permanent and unconditional and applies to all Chapter 27 goods regardless of end-use in the pharma chain. This tool separates the Chapter 27 solvent ITC out at the input stage, carves it out of the refund-eligible Net ITC, and displays it in the excluded-ITC audit trail so the RFD-01 preparer has a clean line-item reconciliation for the audit committee and for the GST officer's verification questionnaire.

The Section 54(3) Rule 89(5) refund runs on a monthly cycle keyed to the tax period. Step 1 — Tax period close: the plant closes the GST tax period (month) with GSTR-1 (outward supply) filed by the 11th of the following month and GSTR-3B (auto-populated liability and ITC availed) filed by the 20th of the following month. The Net ITC availed on goods purchases for the month is now locked in the electronic credit ledger. Step 2 — RFD-01 preparation: the plant's indirect-tax head or the retained consulting firm computes the Rule 89(5) refund quantum plant-by-plant, applies the amended Net ITC (goods only, excluding Ch 27 solvents blocked per N09/2022 and excluding input services + capital goods excluded per N14/2022), pulls the Adjusted Total Turnover per the definition, subtracts the tax payable on inverted-rated supply from the pro-rata Net ITC, and prepares the RFD-01 with Statement 1A (declaration of the refund claim) and the supporting HSN-wise inward and outward supply schedules. Step 3 — RFD-01 filing: filed on the GST portal within two years from the relevant date (Section 54(1)). For monthly cycle discipline, plants file within 30-45 days of tax-period close. Step 4 — Provisional refund: the proper officer sanctions provisional refund of up to 90 percent within 7 days per Rule 91, subject to the deficiency memo route in RFD-03 for any query. Step 5 — Final sanction: post any verification (invoice vetting, HSN classification, ITC eligibility questions), the final RFD-06 sanction and RFD-05 payment order flow, with bank credit typically 30-60 days from filing for clean cycles. What every plant-month must track: (a) tax-period close date, (b) RFD-01 filing date, (c) RFD-02 acknowledgement receipt, (d) RFD-03 deficiency memo receipt (if any), (e) RFD-06 sanction, (f) RFD-05 payment advice, (g) bank credit landing date. The gap between (a) tax-period close and (g) bank credit is the working-capital-carry the CFO monitors. GST Council FAQ Q10 of the 56th Council specifically pledged an expedited Section 54(3) cycle for pharma to keep this gap short.

The 56th GST Council meeting was held on 03-September-2025 and its decisions, notified for implementation from 22-September-2025, constituted the largest post-GST rate rationalisation for pharmaceuticals since the introduction of GST in 2017. All drugs moved to a flat 5 percent output GST (from the pre-transition split of 5 percent for Ch 3003 non-formulation and 12 percent for Ch 3004 formulation). All HSN 9018-9022 medical devices moved from 18 percent to 5 percent, sweeping in diagnostic devices, dental instruments, ECG and X-ray equipment, orthopaedic implants, catheters, sutures, syringes, blood-collection systems, patient monitors, ultrasound and MRI. A specified schedule of life-saving drugs — cancer chemotherapy, HIV antiretrovirals, tuberculosis first-line and second-line regimens, and rare-disease specified molecules — moved to a nil rate. The Council anticipated that this rationalisation deepens the inversion for every formulator, and issued a set of FAQs to clarify the transition. FAQ Q10 explicitly recognised the deepened inversion and pledged that Section 54(3) refunds under Rule 89(5) would be processed on an expedited cycle for pharma. FAQ Q25 clarified the straddle-invoice treatment (goods dispatched pre-cutover and received post-cutover — see the sibling article on pharma straddle-invoice reconciliation). FAQ Q51 addressed the medical-devices rate transition specifically, including guidance on the ITC treatment for stock-in-hand at the plant, at the distributor, and at the hospital as of the cutover date. In cash terms, the expedited cycle pledge means the Rule 89(5) working-capital carry for a well-managed pharma manufacturer should now stay under 45-60 days, versus the 90-120 days observed in the pre-2025 cycle. The tool computes the refund quantum per plant-month and, tied to the plant's RFD-01 filing calendar, gives the CFO a rolling forecast of expected refund cash inflow that feeds the monthly cash-flow committee agenda. Illustrative — verify the current sanction cadence and expedited-track parameters with the CBIC's post-56th-Council FAQ updates and with your indirect-tax head before finalising any actual claim.